Komori
ReproCELL (4978) · InitiativeAdvanced

Improving operational efficiency and simplifying the organization through mergers of overseas subsidiaries

First written in FY2017-Q1. 1 of 3 entries say "Achieved", first in FY2017-Q2. Latest entry: FY2017.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017-Q1AchievedFY2017-Q2 – FY20172016: 220162017: 12017
Same theme, other companies
Optimization of Business Operations through Business Segment and Subsidiary RestructuringA theme 70 companies write about · 0 as a headwind · 57 as a tailwind

The whole theme swung hardest in 2025: 8 of 37 companies on the "Worse" side.

21 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 70 companies compared. The sentences above are computed from all 70.
Full recordFilings, disclosures and news, newest first
  1. FY2017AdvancedAnnual report

    「Through this integration, we reduced expenses by eliminating overlapping functions in the administrative and marketing divisions, while seeking to realize technological synergies among the subsidiaries and improve the efficiency of sales activities in the technology and sales divisions.」

    The Company describes the effects following completion of the integration of its U.S. and U.K. subsidiaries, including the elimination of overlapping functions, expense reductions, technological synergies, and more efficient sales activities.
  2. FY2017-Q2AchievedAnnual report

    「The Company merged 3 U.S. companies (Stemgent, BioServe, and Biopta Inc.) and 2 U.K. companies (Reinnervate and Biopta), respectively, and reorganized them as ReproCELL USA Inc. and ReproCELL Europe Ltd.」

    The mergers of 3 U.S. companies and 2 U.K. companies and their reorganization into regional entities have been completed. The Company plans to realize the benefits, including greater efficiency and lower selling, general and administrative expenses, going forward.
  3. FY2017-Q1First statedAnnual report

    「In May 2016, as part of the reorganization of the Group to achieve its medium-term management plan, the Company resolved on a policy concerning the merger of its consolidated subsidiaries in order to further improve operational efficiency, simplify the organization, and maximize synergies in technology development.」

    The Company resolved on a policy to merge 2 U.S. companies and 2 U.K. companies, respectively, and reorganize them into regional entities.
Moved together

"Differentiation through a broad lineup of research reagents, cell products and contract services" moved the same way as this thread, in the same document, in 2 of its 3 moves.

2222★1234
  1. ★This thread
  2. 1Differentiation through a broad lineup of research reagents, cell products and contract services2×
  3. 2Global expansion leveraging sales channels in Japan, the US and Europe2×
  4. 3Clinical-grade development of research reagents and sales of products for regenerative medicine2×
  5. 4Expansion of the Clinical Testing Business Through New Projects and New Testing Items2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Improving operational efficiency and simplifying the organization through mergers of overseas subsidiaries | ReproCELL Incorporated (4978) | Komori